Abstract

Advancing Pre-Clinical Safety Assessment with Organs-on-Chips

Rhiannon David, Senior Scientist, AstraZeneca

Organs-on-chips (microphysiological systems (MPS)) aim to recapitulate the architecture, cell-cell interactions, and microenvironment of different tissues, which is more representative of their complex in vivo biology. Human-sourced MPS provide an opportunity to generate safety and efficacy data for drug development with improved clinical relevance over more traditional animal models. This presentation will outline the context of use of MPS at AstraZeneca and give examples of data generated from these systems, with a focus on the development of a bone marrow-on-a-chip to better predict clinically-observed toxicity.